Chronic treatment with desipramine facilitates its effect on extracellular noradrenaline in the rat hippocampus: studies on the role of presynaptic alpha2-adrenoceptors

Naunyn Schmiedebergs Arch Pharmacol. 2001 Jan;363(1):66-72. doi: 10.1007/s002100000334.

Abstract

Adaptive phenomena such as desensitization of autoreceptors are considered an important factor in the achievement of therapeutic efficacy of antidepressant drugs after chronic treatment. We have studied whether a chronic treatment with desipramine had a greater effect than a single dose on the extracellular concentrations of noradrenaline in the dorsal hippocampus. Administration of 10 mg/kg i.p. desipramine once daily for 14 days significantly raised the basal extracellular noradrenaline in the dorsal hippocampus 24 h but not 48 h after the last drug injection. A challenge dose of desipramine increased extracellular noradrenaline in rats treated chronically with vehicle and desipramine. The effect was significantly higher in rats treated chronically with desipramine 48 h but not 24 h after the last injection. An intraperitoneal administration of the alpha2-adrenoceptor agonist clonidine at the dose of 10 microg/kg significantly reduced extracellular noradrenaline in the control group but not in animals chronically treated with desipramine whereas 30 microg/kg clonidine produced a similar decrease in both groups. Three concentrations of clonidine (0.05, 0.5 and 1 microM) infused into the hippocampus significantly reduced extracellular noradrenaline to a similar extent in rats chronically treated with saline or desipramine. Fourty-eight hours after the last injection of the chronic treatment, [3H]RX-821002 binding to alpha2-adrenoceptors in the rat locus coeruleus measured by autoradiography was not significantly modified. A slight (17%) but significant decrease of neuronal uptake of [3H]noradrenaline was found in synaptosome preparations from dorsal hippocampus of rats chronically treated with desipramine, but this was likely due to a decrease in affinity. The results suggest that a repeated treatment with desipramine (10 mg/kg i.p. once daily for 14 days) facilitates its effect on extracellular noradrenaline in the dorsal hippocampus and induces adaptive changes probably involving desensitization of alpha2-adrenoceptors, with no changes in their density, on noradrenergic neurons in the locus coeruleus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic Uptake Inhibitors / pharmacology*
  • Adrenergic alpha-Agonists / pharmacology
  • Animals
  • Binding, Competitive / drug effects
  • Clonidine / pharmacology
  • Desipramine / pharmacology*
  • Dose-Response Relationship, Drug
  • Extracellular Space / chemistry
  • Extracellular Space / drug effects
  • Extracellular Space / metabolism
  • Hippocampus / drug effects*
  • Hippocampus / metabolism
  • Idazoxan / analogs & derivatives*
  • Idazoxan / metabolism
  • Locus Coeruleus / drug effects
  • Locus Coeruleus / metabolism
  • Male
  • Microdialysis
  • Norepinephrine / metabolism*
  • Norepinephrine / pharmacokinetics
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Adrenergic, alpha-2 / metabolism
  • Receptors, Adrenergic, alpha-2 / physiology
  • Receptors, Presynaptic / metabolism
  • Receptors, Presynaptic / physiology
  • Synaptosomes / drug effects
  • Synaptosomes / metabolism
  • Time Factors
  • Tritium

Substances

  • Adrenergic Uptake Inhibitors
  • Adrenergic alpha-Agonists
  • Receptors, Adrenergic, alpha-2
  • Receptors, Presynaptic
  • Tritium
  • 2-methoxyidazoxan
  • Clonidine
  • Desipramine
  • Norepinephrine
  • Idazoxan